tbuckley/cabot-search huggingface dataset:
Evaluation of tuberculosis screening of immigrants in the Netherlands
Authors: Sarah van de Berg, Connie Erkens, Job van Rest, Susan van den Hof, Margreet Kamphorst, Sytze Keizer, Gerard de Vries
Journal: European Respiratory Journal (2017)

In European Union/European Economic Area countries, a large proportion of patients with tuberculosis (TB) are born in or are citizens of a country different from the notifying country [1]. Immigrants have an increased risk for TB, depending on the TB incidence in their country of origin, conditions of their migration and duration of stay in the host country [2]. In low TB-incidence countries, systematic screening of immigrants at high risk for TB pre- or post-entry may be considered a key intervention in the progress towards TB elimination [3, 4]. However, current screening policies and practices in European low-incidence countries differ substantially [5, 6]. Evaluation of TB screening needed to periodically assess its effectiveness and inform policy decision <http://ow.ly/F8zQ30f7l9D>
Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome
Authors: Bernhard N. Bohnert, Martina Menacher, Andrea Janessa, Matthias Wörn, Anja Schork, Sophie Daiminger, Hubert Kalbacher, Hans-Ulrich Häring, Christoph Daniel, Kerstin Amann, Florian Sure, Marko Bertog, Silke Haerteis, Christoph Korbmacher, Ferruh Artunc
Journal: Kidney International (2017)
A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease
Authors: Stephen K. Van Den Eeden, Ruixiao Lu, Nan Zhang, Charles P. Quesenberry, Jun Shan, Jeong S. Han, Athanasios C. Tsiatis, Amethyst D. Leimpeter, H. Jeffrey Lawrence, Phillip G. Febbo, Joseph C. Presti
Journal: European Urology (2017)
Sequential first-line therapy of metastatic colorectal cancer (mCRC) starting with fluoropyrimidine (FP) plus bevacizumab (BEV) vs. initial FP plus irinotecan (IRI) and BEV: German AIO KRK0110 (ML22011) study
Authors: D.P. Modest, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, J. Uhlig, M. Schenk, J. Freiberg-Richter, B. Peuser, C. Denzlinger, C. Peveling Genannt Reddemann, U. Graeven, G. Schuch, I. Schwaner, A. Stahler, A. Jung, S. Held, S. Stintzing, C. Giessen-Jung, V. Heinemann
Journal: Annals of Oncology (2017)
Targeted Therapy for Adult Leukemia
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disorazole C1: A potent antimitotic agent that induces premature senescence
Authors: Marni Brisson, Bethany Petrik, Thomas Graham, William Saunders, Fengfeng Xu, Jane Stout, Claire Walczak, Alexander Ducruet, Peter Wipf, John Lazo
Journal: Cancer Research (2007)

1219   Disorazole C 1  is a potent, cytotoxic natural product, with IC 50  values of  1  disrupted microtubules in cells as early as 24 h after treatment, causing multinucleation and disorganized microtubules at interphase and misaligned chromosomes at the metaphase plate during mitosis. A549 cells that survived a 7 day treatment of disorazole C 1  displayed an enlarged, flattened morphology similar to senescent cells treated with doxorubicin. These surviving cells displayed the characteristic β-galactosidase staining at pH 6.0 seen in senescent cells and changes in cell cycle markers indicative of premature or hypermitogenic senescence. A549 cells treated with the IC 50  concentration of disorazole C 1  (2 nM) for 7 days had increased protein levels of cyclin D, p53 and cyclin-dependent kinase inhibitor p21 as detected by Western blot. This resulted in decreased phosphorylation of Rb (Ser780) and a decrease in total Rb protein levels. A dramatic decrease in BrdU incorporation was also observed in disorazole C 1  treated cells, further implicating the induction of senescence. Finally, DC3F/VCRd-5L cells, which are >2000-fold resistant to vincristine as compared to DC3F cells, were only 5-fold resistant to disorazole C 1 . These results provide the first evidence of a microtubule disrupter that induces premature senescence.
Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)
Authors: M. Lim, A. Omuro, G. Vlahovic, D.A. Reardon, S. Sahebjam, T. Cloughesy, J. Baehring, N. Butowski, V. Potter, R. Zwirtes, P. Paliwal, M. Carleton, J. Sampson, A.A. Brandes
Journal: Annals of Oncology (2017)
Radiomics: the bridge between medical imaging and personalized medicine
Authors: Philippe Lambin, Ralph T.H. Leijenaar, Timo M. Deist, Jurgen Peerlings, Evelyn E.C. de Jong, Janita van Timmeren, Sebastian Sanduleanu, Ruben T.H.M. Larue, Aniek J.G. Even, Arthur Jochems, Yvonka van Wijk, Henry Woodruff, Johan van Soest, Tim Lustberg, Erik Roelofs, Wouter van Elmpt, Andre Dekker, Felix M. Mottaghy, Joachim E. Wildberger, Sean Walsh
Journal: Nature Reviews Clinical Oncology (2017)
Botulismo en la Unión Europea
Authors: H Therre
Journal: Eurosurveillance (1999)

La toxina botulinica fue descrita por primera vez como una potente neurotoxina a finales del siglo XVIII. En la actualidad, se distinguen tres formas principales de botulismo distintas desde un punto de vista epidemiologico y clinico: el botulismo transmitido por alimentos, que resulta de la ingestion de alimentos contaminados con la toxina preformada; el botulismo del lactante, debido a la formacion endogena de la toxina mediante la germinacion de esporas de Clostridium botulinum en el intestino del lactante; y el botulismo por heridas, causado por organismos que se multiplican y producen la toxina en heridas contaminadas. Se conocen siete tipos de C. botulinum (A a G), diferenciables entre si por las caracteristicas antigenicas de la toxina que producen. Los tipos A, B, E y, con menor frecuencia, F son patogenos para el ser humano (1).
Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma
Authors: W. Boxtel, L.D. Locati, S. Tooten, E. Bos, C. Bergamini, A.C.H. van Engen-van Grunsven, E. Boon, E. Fiets, S. Cavalieri, G. Verhaegh, J. Schalken, L. Licitra, C.M.L. Herpen
Journal: Annals of Oncology (2017)
A Population-Based Assessment of Emergency Department Observation Status for Older Adults With Cancer
Authors: Allison Lipitz-Snyderman, Adam Klotz, Renee L. Gennarelli, Jeffrey Groeger
Journal: Journal of the National Comprehensive Cancer Network (2017)

Background: Hospitals' use of observation status for patients with cancer presenting to the emergency department (ED) is not well understood. This model of care delivery may be a viable alternative to inpatient admission for patients with cancer presenting with certain conditions. Our objective was to assess the use of observation status among Medicare beneficiaries with and without cancer. Methods: Population-based SEER-Medicare data were used to assess differences in the use of observation status between Medicare beneficiaries aged ≥66 years with and without cancer using a matched analysis (n=151,183 per cohort). We assessed the ratio of observation unit use to inpatient admission, between cancer and noncancer cohorts, and for patients diagnosed with breast, colon, lung, and prostate cancers. Poisson regression models were used to calculate observation rate estimates and 95% CIs while adjusting for selected patient characteristics. Results: When considering the volume of hospitalizations, observation status is used less frequently among beneficiaries with cancer than those without (43 vs 69 observation status visits per 1,000 inpatient admissions, respectively). The estimated observation rate per 1,000 inpatient admissions was higher for beneficiaries aged <75 years versus those aged ≥75 years, those with a Charlson comorbidity index of 0 vs 1 or ≥2, and those without a prior hospitalization versus those with ≥1 prior hospitalizations. Patients with breast and prostate cancers had higher adjusted and unadjusted observation rates per 1,000 inpatient admissions compared with those with colon and lung cancers. Conclusions: Observation status is used proportionately less for beneficiaries with cancer than those without. There may be opportunities to develop standards for ED staff to manage certain conditions for patients with cancer in observation status, and to reserve hospital resources for those who need it most.
PTH-074 Baseline calprotectin does not predict response to biological therapy in ulcerative colitis
Authors: D Storey, T Skouras, A Bond, S Dodd, S Subramanian
Journal: Gut (2017)

Introduction  Response to biological drugs in ulcerative colitis (UC) is variable with induction response rates of 64.5% (vs 29.3% for placebo), 50.4% (vs 34.6% for placebo), 51.0% (vs 30.3% for placebo), 47.1% (vs 25.5% for placebo) for infliximab, adalimumab, golimumab and vedolizumab, respectively. Apart from prior exposure to anti-tumour necrosis factor (anti-TNF) agents and concurrent immunomodulatory therapy, predictors of clinical response and remission to biological drugs have not been identified. We sought to investigate the utility of baseline faecal calprotectin (FC) and early change in FC in predicting clinical response and remission to biological therapy in UC.  Method  Patients who were commenced on any biological therapy for UC and had a baseline FC at the time of commencement were included in this retrospective study. Disease activity was monitored serially by calculation of Simple Clinical Colitis Activity Index (SCCAI) or by Physician global assessment (PGA) or by treatment persistence. Clinical response was defined as decrease in SCCAI≥3 or a decrease in PGA score from baseline to follow up. The ability of FC and fold change in FC to predict response and remission at 6 months was estimated using Mann-Whitney test.  Results  A total of 94 patients were commenced on biological therapy of who 70 commenced anti-TNF therapy and 24 commenced vedolizumab with a mean age of 41.8 (SD:+18.2). Fifty-one (72%) and 39 (55%) patients commencing anti-TNF therapy were on concurrent immunomodulators (IM) and steroids respectively compared to 9 (38%) and 16 (67%) patients respectively for vedolizumab. Sixteen (67%) patients treated with vedolizumab had prior exposure to anti-TNF agents compared to 4 (6%) in the anti-TNF treated group. The 6 month response among patients treated with vedolizumab and anti-TNF agents was 77.2% and 73.5% respectively. The calprotectin values were similar for responders (428.5 (72, 2100) [n=16]) and non-responders (600 (107, 2100) [n=5]) to vedolizumab (p=0.56). Similarly, responders (909 (13, 2100) [n=28]) and non-responders (850 (240, 2100) [n=13]) to anti-TNF agents had comparable calprotectin values at baseline, p=0.93  Conclusion  In a single centre series of biologic treated UC patients, baseline FC did not predict clinical response at 6 months.  Disclosure of Interest  None Declared
Engineering a highly elastic human protein–based sealant for surgical applications
Authors: Nasim Annabi, Yi-Nan Zhang, Alexander Assmann, Ehsan Shirzaei Sani, George Cheng, Antonio D. Lassaletta, Andrea Vegh, Bijan Dehghani, Guillermo U. Ruiz-Esparza, Xichi Wang, Sidhu Gangadharan, Anthony S. Weiss, Ali Khademhosseini
Journal: Science Translational Medicine (2017)

A highly elastic and adhesive photocrosslinkable surgical sealant using a modified human protein controls liquid leakages without the need for suturing.
Editorial: Bone Reading to Predict the Future
Authors: Martin Englund, Aleksandra Turkiewicz, Pawel Podsiadlo
Journal: Arthritis & Rheumatology (2017)

Human skeletal remains may provide information about health status and injuries from hundreds of thousands of years ago. However, the bones in living individuals have the potential to tell us something about future health as well. In the current issue of Arthritis & Rheumatology, Kraus et al report data of prediction of osteoarthritis (OA) progression using tibial subchondral trabecular bone texture (TBT) from plain knee radiographs (1). The ability of medial TBT was assessed to predict pain progression (an increase in WOMAC score), radiographic OA progression (a loss in joint space width [JSW]), and OA status (a combination of pain and radiographic OA progression), over 24-48 months.

This article is protected by copyright. All rights reserved.
Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease
Authors: J. Cortés, H.S. Rugo, S.M. Tolaney, V. Diéras, D. Patt, H. Wildiers, S. Nanda, A. Koustenis, M.N. Dickler, J. Baselga
Journal: Annals of Oncology (2017)
PPARγ ligands induce cell growth inhibition, apoptosis and interact with EGFR pathway and inhibitors in cancer cells
Authors: Letizia Porcelli, Amalia Azzariti, Grazia Simone, Sara Gagliardi, Antonio Laghezza, Giuseppe Fracchiolla, Fulvio Loiodice, Angelo Paradiso
Journal: Cancer Research (2007)

5420   Cancer cells are often characterised by an over-expression of PPARα and γ, members of the nuclear receptor superfamily, which may therefore be potential targets for biological therapy. In this report, we provide data on the in vitro anti-cancer activity of a new series of clobifric acid derivatives with PPARα/γ agonist activities. 10 compounds were synthesized and their effects on cancer cell growth, apoptosis and signalling pathways were evaluated. Breast, colon and liver cancer cell lines (HepG2, MCF7, MDA-MB- 231, HT-29, LoVo and HCT-15) were utilised in all the experiments. All agents showed an IC50 range between 20μM and 100μM; among them, the main active ones were LT127 and LT160 (two enantiomers). They induced apoptosis after 1-2 days exposure, with at least a 20% increase in annexin V positive cells. There was also a slight modification of cell cycle progression, with cells accumulating at the G0/G1 phase. Preliminary results with a specific PPARγ irreversible inhibitor, showed that the relationship between the drugs’ effects and PPARγ activation is cell line dependent. Furthermore, as already reported for troglitazone (the reference compound), 1 day exposure to our compounds stimulated the proliferation pathway, with increased expression of phosphorylated Erk1/2, and inhibited the survival pathway, with increased PTEN expression and consequently reduction of p-Akt expression level, after 1 day-drug exposure. Surprisingly, after 2 days drugs exposure, PTEN was strongly inhibited with a consequent increase of p-Akt level, suggesting that combinations of these drugs with agents acting upstream or downstream of the PI3K/Akt pathway are worth investigation. In HepG2 cells, combination of the PPARγ ligands with gefitinib or rapamycin enhanced growth inhibition and increased apoptosis. Further studies are required to fully evaluate the anti-cancer potential of these clofibric acid derivatives. However, further experiments will clarify if these effects are cell line- and schedule-dependent.  Gefitinib is a trademark of the AstraZeneca group of companies
Targeting CXCR4 and FAK in non-small cell lung carcinomas with co-inactivated p53 and PTEN tumor suppressors
Authors: A. Podolski-Renic, M. Dragoj, S. Stojkovic, J. Dinic, J. Bankovic, E. Sereti, S. Jovanovic Stojanov, K. Dimas, M. Pesic, T. Stankovic
Journal: Annals of Oncology (2017)
Abstract 12968: Early AV Conduction Recovery After Pacemaker Placement for High-Degree AV Block Secondary to Transcatheter Aortic Valve Replacement
Authors: Colin A Raelson, James Gabriels, Jonathan Ruan, James E Ip, George Thomas, Christopher F Liu, Jim W Cheung, Bruce B Lerman, Apoor Patel, Steven M Markowitz
Journal: Circulation (2016)

Introduction: Recovery of conduction has been demonstrated in &gt;50% of patients who receive pacemakers (PPMs) for high-degree atrioventricular block (HDAVB) after trans-catheter aortic valve replacement (TAVR). Little information is available about the time course of conduction recovery in these patients, and there is little comparative data regarding resolution of AV block after balloon-expandable compared to self-expanding valves. Methods: A retrospective review was performed of patients who underwent TAVR with balloon and self-expanding valves and required PPMs for HDAVB at 2 institutions. Serial PPM interrogations were analyzed to detect recovery of AV conduction. Analysis was performed to identify predictors and timing of conduction recovery. Results: Of a total population of 578 patients, 54 (9.3%) received PPMs for HDAVB. In multivariate analysis, predictors of HDAVB requiring a PPM included right bundle branch block (OR 5.99 [3.08 -11.6]), atrial fibrillation (OR 1.87 [1.02-3.45]), and self-expanding valves (OR 3.45 [1.85-6.43]). Of the 54 patients who received PPMs, 38 had follow-up sufficient to evaluate AV conduction recovery. Of these, 23 (61%) showed recovery of AV nodal conduction; 20 had already recovered by their first interrogation a median of 22 days (IQR 14-31) post PPM placement (figure). There were no statistically significant predictors of AV nodal conduction recovery, including type of valve implanted. For those who recovered conduction, 9/23 (39%) had ventricular pacing &gt;50% of the time on their final interrogation, of whom 5 had programmed AV intervals &lt;200 msec. Conclusions: A majority of patients who receive PPMs for HDAVB after TAVR recover AV conduction during follow-up, and in most patients conduction recovery occurs within weeks. These findings imply that longer observation periods may be appropriate after TAVR before PPM implantation, and programming that minimizes ventricular pacing may be beneficial.
Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine in patients with stage III colorectal cancer: Updated results of Japan Clinical Oncology Group study (JCOG0910)
Authors: T. Hamaguchi, Y. Shimada, J. Mizusawa, T. Sato, T. Kato, K. Takahashi, K. Sugihara, Y. Saida, H. Ike, K. Hase, T. Masaki, M. Shiozawa, A. Sugita, J. Nishimura, Y. Munakata, S. Ikeda, K. Nakamura, H. Fukuda
Journal: Annals of Oncology (2017)
Epidemiología de infecciones por Mycoplasma pneumoniae en Polonia: 28 años de vigilancia en Varsovia, 1970-1997
Authors: W Rastawicki, S Kaluzewski, M Jagielski, R Gierczyski
Journal: Eurosurveillance (1998)

Mycoplasma pneumoniae es una causa frecuente de enfermedades del tracto respiratorio inferior en las personas, especialmente en ninos mayores, adolescentes y adultos jovenes. Las infecciones son endemicas en ciudades y se observan aumentos epidemicos a intervalos de 4 a 7 anos. M. pneumoniae crece lentamente; su cultivo es dificil y lleva tiempo. Todo ello hace que el diagnostico de infecciones por M. pneumoniae se base, por lo general, en la serologia, principalmente por pruebas de fijacion del complemento (FC) (1,2).
Annals Graphic Medicine - Every Little Bit
Authors: Allison K. Weinstock
Journal: Annals of Internal Medicine (2017)

Web Exclusives3 October 2017Annals Graphic Medicine - Every Little BitFREEAllison K. Weinstock, BAAllison K. Weinstock, BASearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G17-0006 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: The author has disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G17-0006.Corresponding Author: Allison K. Weinstock, BA, Penn State College of Medicine, 500 University Drive, Hershey, PA 17033; e-mail, allison.k.[email protected]com.Author Contributions: Conception and design: A.K. Weinstock.Drafting of the article: A.K. Weinstock.Final approval of the article: A.K. Weinstock. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 October 2017Volume 167, Issue 7Page: W41-W46KeywordsConflicts of interestDisclosureHealth care ePublished: 3 October 2017 Issue Published: 3 October 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Optical Frequency Domain Imaging Versus Intravascular Ultrasound in Percutaneous Coronary Intervention (OPINION Trial)
Authors: Hiromasa Otake, Takashi Kubo, Hachidai Takahashi, Toshiro Shinke, Takayuki Okamura, Kiyoshi Hibi, Gaku Nakazawa, Yoshihiro Morino, Junya Shite, Tetsuya Fusazaki, Ken Kozuma, Tetsuya Ioji, Hideaki Kaneda, Takashi Akasaka
Journal: JACC. Cardiovascular imaging (2017)

The authors sought to clarify how intravascular ultrasound (IVUS) and optical coherence tomography affect percutaneous coronary intervention (PCI) with current-generation drug-eluting stents in a pre-specified substudy of the OPINION (OPtical frequency domain imaging versus INtravascular ultrasound in percutaneous coronary interventiON) trial, a multicenter, prospective, randomized, noninferiority trial comparing optical frequency domain imaging (OFDI)-guided PCI with IVUS-guided PCI.The impact of these 2 imaging modalities in guiding PCI remains unknown.Of 829 patients enrolled in the OPINION trial, 106 were included in the present imaging substudy. Their PCI was guided by either IVUS or OFDI, but all patients were imaged by both modalities after PCI and by OFDI at 8 months. Angiographic, OFDI, and IVUS images were analyzed by independent core laboratories, and statistical analysis was done independently by a dedicated institution.A total of 103 patients underwent either OFDI-guided (n = 54) or IVUS-guided (n = 49) PCI. Immediately after PCI, OFDI-guided PCI was associated with a smaller trend of minimum stent area (5.28 ± 1.65 mm2 vs. 6.12 ± 2.34 mm2; p = 0.088), fewer proximal stent-edge hematomas (p = 0.04), and fewer irregular protrusions (p = 0.014) than IVUS-guided PCI. At 8 months, the neointima area tended to be smaller in the OFDI-guided PCI group than in the IVUS-guided PCI group (0.56 ± 0.30 mm2 vs. 0.80 ± 0.65 mm2; p = 0.057), although the percentage of uncovered struts was significantly higher in the OFDI-guided PCI group than in the IVUS-guided PCI group (6.97 ± 7.03% vs. 4.67 ± 6.43%; p = 0.039). The minimum lumen area was comparable in both groups (p = 0.18).There were several differences in local findings between OFDI- and IVUS-guided PCI as expected given the different protocols for stent sizing in the 2 groups. The minimum lumen area at the 8-month follow-up was comparable, suggesting that OFDI- and IVUS-guided PCI are similarly feasible using the current-generation drug-eluting stents. (OPtical frequency domain imaging versus INtravascular ultrasound in percutaneous coronary interventiON; NCT01873222).